BIOMARIN PHARMACEUTICAL INC Depreciation
BIOMARIN PHARMACEUTICAL INC (BMRN) reported Depreciation of $9.60 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- BIOMARIN PHARMACEUTICAL INC depreciation for the quarter ending 2026-06-30 was $9.60M, a 9.43% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC depreciation for the quarter ending 2026-03-31 was $8.80M, a 37.59% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC depreciation for the quarter ending 2025-12-31 was $13.20M, a 13.79% increase year-over-year.
- BIOMARIN PHARMACEUTICAL INC depreciation for the quarter ending 2025-09-30 was $10.60M, a 2.75% decline year-over-year.
- BIOMARIN PHARMACEUTICAL INC depreciation for fiscal 2025 was $48.50M, a 4.08% increase from fiscal 2024.
- BIOMARIN PHARMACEUTICAL INC depreciation for fiscal 2024 was $46.60M, a 15.63% increase from fiscal 2023.
- BIOMARIN PHARMACEUTICAL INC depreciation for fiscal 2023 was $40.30M, a 4.40% increase from fiscal 2022.
- BIOMARIN PHARMACEUTICAL INC depreciation for fiscal 2022 was $38.60M, a 16.27% decline from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 3 month as first filed | Depreciation 6 month | Depreciation 6 month as first filed | Depreciation 9 month | Depreciation 9 month as first filed | Depreciation 12 month | Depreciation 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $9.60M 10-Q · filed 2026-08-06 | $18.40M 10-Q · filed 2026-08-06 | $31.60M derived: sum of 3 quarters · filed 2026-08-06 | $42.20M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $8.80M 10-Q · filed 2026-05-05 | $22.00M derived: sum of 2 quarters · filed 2026-05-05 | $32.60M derived: sum of 3 quarters · filed 2026-05-05 | $43.20M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $13.20M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $23.80M derived: sum of 2 quarters · filed 2026-02-26 | $34.40M derived: sum of 3 quarters · filed 2026-08-06 | $48.50M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $10.60M 10-Q · filed 2025-10-28 | $21.20M derived: sum of 2 quarters · filed 2026-08-06 | $35.30M 10-Q · filed 2025-10-28 | $46.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $10.60M 10-Q · filed 2026-08-06 | $24.80M 10-Q · filed 2026-08-06 | $36.30M derived: sum of 3 quarters · filed 2026-08-06 | $47.20M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $14.10M 10-Q · filed 2026-05-05 | $25.70M derived: sum of 2 quarters · filed 2026-05-05 | $36.60M derived: sum of 3 quarters · filed 2026-05-05 | $48.10M derived: sum of 4 quarters · filed 2026-05-05 | ||||
| 2024-12-31 | $11.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $22.50M derived: sum of 2 quarters · filed 2026-02-26 | $34.00M derived: sum of 3 quarters · filed 2026-02-26 | $46.60M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $10.90M 10-Q · filed 2025-10-28 | $22.40M derived: sum of 2 quarters · filed 2025-10-28 | $35.00M 10-Q · filed 2025-10-28 | $45.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $11.50M 10-Q · filed 2025-08-05 | $24.10M 10-Q · filed 2025-08-05 | $34.80M derived: sum of 3 quarters · filed 2026-02-26 | $44.70M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $12.60M 10-Q · filed 2025-05-02 | $23.30M derived: sum of 2 quarters · filed 2026-02-26 | $33.20M derived: sum of 3 quarters · filed 2026-02-26 | $42.60M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $10.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $20.60M derived: sum of 2 quarters · filed 2026-02-26 | $30.00M derived: sum of 3 quarters · filed 2026-02-26 | $40.30M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $9.90M 10-Q · filed 2024-10-31 | $19.30M derived: sum of 2 quarters · filed 2024-10-31 | $29.60M 10-Q · filed 2024-10-31 | $38.30M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-06-30 | $9.40M 10-Q · filed 2024-08-05 | $19.70M 10-Q · filed 2024-08-05 | $28.40M derived: sum of 3 quarters · filed 2025-02-24 | $37.10M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2023-03-31 | $10.30M 10-Q · filed 2024-04-26 | $19.00M derived: sum of 2 quarters · filed 2025-02-24 | $27.70M derived: sum of 3 quarters · filed 2025-02-24 | $37.20M derived: sum of 4 quarters · filed 2025-02-24 | ||||
| 2022-12-31 | $8.70M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-24 | $17.40M derived: sum of 2 quarters · filed 2025-02-24 | $26.90M derived: sum of 3 quarters · filed 2025-02-24 | $38.60M 10-K · filed 2025-02-24 | ||||
| 2022-09-30 | $8.70M 10-Q · filed 2023-11-02 | $18.20M derived: sum of 2 quarters · filed 2023-11-02 | $29.90M 10-Q · filed 2023-11-02 | $40.30M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-06-30 | $9.50M 10-Q · filed 2023-08-02 | $21.20M 10-Q · filed 2023-08-02 | $31.60M derived: sum of 3 quarters · filed 2024-02-26 | $43.00M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2022-03-31 | $11.70M 10-Q · filed 2023-04-28 | $22.10M derived: sum of 2 quarters · filed 2024-02-26 | $33.50M derived: sum of 3 quarters · filed 2024-02-26 | $45.30M derived: sum of 4 quarters · filed 2024-02-26 | ||||
| 2021-12-31 | $10.40M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-26 | $21.80M derived: sum of 2 quarters · filed 2024-02-26 | $33.60M derived: sum of 3 quarters · filed 2024-02-26 | $46.10M 10-K · filed 2024-02-26 | ||||
| 2021-09-30 | $11.40M 10-Q · filed 2022-10-28 | $23.20M derived: sum of 2 quarters · filed 2022-10-28 | $35.70M 10-Q · filed 2022-10-28 | $47.60M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-06-30 | $11.80M 10-Q · filed 2022-08-04 | $24.30M 10-Q · filed 2022-08-04 | $36.20M derived: sum of 3 quarters · filed 2023-02-27 | $47.30M derived: sum of 4 quarters · filed 2023-02-27 | ||||
| 2021-03-31 | $12.50M 10-Q · filed 2022-04-29 | $22.59M 10-Q · filed 2021-04-30 | $24.40M derived: sum of 2 quarters · filed 2023-02-27 | $35.50M derived: sum of 3 quarters · filed 2023-02-27 | $45.20M derived: sum of 4 quarters · filed 2023-02-27 | |||
| 2020-12-31 | $11.90M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | $23.00M derived: sum of 2 quarters · filed 2023-02-27 | $32.70M derived: sum of 3 quarters · filed 2023-02-27 | $43.00M 10-K · filed 2023-02-27 | $88.17M 10-K · filed 2021-02-26 | |||
| 2020-09-30 | $11.10M 10-Q · filed 2021-10-29 | $22.19M 10-Q · filed 2020-11-06 | $20.80M derived: sum of 2 quarters · filed 2021-10-29 | $31.10M 10-Q · filed 2021-10-29 | $65.75M 10-Q · filed 2020-11-06 | $26.91M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-06-30 | $9.70M 10-Q · filed 2021-07-30 | $22.04M 10-Q · filed 2020-08-05 | $20.00M 10-Q · filed 2021-07-30 | $43.56M 10-Q · filed 2020-08-05 | $15.81M derived: sum of 3 quarters · filed 2022-02-25 | $40.05M derived: sum of 4 quarters · filed 2022-02-25 | ||
| 2020-03-31 | $21.52M 10-Q · filed 2021-04-30 | $21.50M 10-Q · filed 2020-05-01 | $6.11M derived: sum of 2 quarters · filed 2022-02-25 | $30.35M derived: sum of 3 quarters · filed 2022-02-25 | $51.88M derived: sum of 4 quarters · filed 2022-02-25 | |||
| 2019-12-31 | -$15.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-25 | $8.83M derived: sum of 2 quarters · filed 2022-02-25 | $30.36M derived: sum of 3 quarters · filed 2022-02-25 | $51.80M 10-K · filed 2022-02-25 | $89.30M 10-K · filed 2020-02-27 | |||
| 2019-09-30 | $24.24M 10-Q · filed 2020-11-06 | $24.20M 10-Q · filed 2019-10-29 | $45.77M derived: sum of 2 quarters · filed 2020-11-06 | $67.21M 10-Q · filed 2020-11-06 | $67.20M 10-Q · filed 2019-10-29 | $90.84M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-06-30 | $21.53M 10-Q · filed 2020-08-05 | $21.50M 10-Q · filed 2019-08-02 | $42.97M 10-Q · filed 2020-08-05 | $43.00M 10-Q · filed 2019-08-02 | $66.60M derived: sum of 3 quarters · filed 2021-02-26 | $93.20M derived: sum of 4 quarters · filed 2021-02-26 | ||
| 2019-03-31 | $21.40M 10-Q · filed 2020-05-01 | $45.08M derived: sum of 2 quarters · filed 2021-02-26 | $71.67M derived: sum of 3 quarters · filed 2021-02-26 | $91.78M derived: sum of 4 quarters · filed 2021-02-26 | ||||
| 2018-12-31 | $23.68M derived: 10-K 12 month − 10-Q/A 9 month · filed 2021-02-26 | $50.27M derived: sum of 2 quarters · filed 2021-02-26 | $70.38M derived: sum of 3 quarters · filed 2021-02-26 | $90.38M 10-K · filed 2021-02-26 | $90.40M 10-K · filed 2019-02-28 | |||
| 2018-09-30 | $26.60M 10-Q/A · filed 2019-11-04 | $46.70M derived: sum of 2 quarters · filed 2019-11-04 | $66.70M 10-Q/A · filed 2019-11-04 | $87.70M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-06-30 | $20.10M 10-Q · filed 2019-08-02 | $40.10M 10-Q · filed 2019-08-02 | $61.10M derived: sum of 3 quarters · filed 2020-02-27 | $80.50M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2018-03-31 | $20.00M 10-Q · filed 2019-04-29 | $41.00M derived: sum of 2 quarters · filed 2020-02-27 | $60.40M derived: sum of 3 quarters · filed 2020-02-27 | $78.30M derived: sum of 4 quarters · filed 2020-02-27 | ||||
| 2017-12-31 | $21.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | $40.40M derived: sum of 2 quarters · filed 2020-02-27 | $58.30M derived: sum of 3 quarters · filed 2020-02-27 | $75.80M 10-K · filed 2020-02-27 | ||||
| 2017-09-30 | $19.40M 10-Q · filed 2018-10-26 | $37.30M derived: sum of 2 quarters · filed 2018-10-26 | $54.80M 10-Q · filed 2018-10-26 | $71.90M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-06-30 | $17.90M 10-Q · filed 2018-08-03 | $35.40M 10-Q · filed 2018-08-03 | $52.50M derived: sum of 3 quarters · filed 2019-02-28 | $75.70M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2017-03-31 | $17.50M 10-Q · filed 2018-04-27 | $34.60M derived: sum of 2 quarters · filed 2019-02-28 | $57.80M derived: sum of 3 quarters · filed 2019-02-28 | $75.00M derived: sum of 4 quarters · filed 2019-02-28 | ||||
| 2016-12-31 | $17.10M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $40.30M derived: sum of 2 quarters · filed 2019-02-28 | $57.50M derived: sum of 3 quarters · filed 2019-02-28 | $73.20M 10-K · filed 2019-02-28 | ||||
| 2016-09-30 | $23.20M 10-Q · filed 2017-10-31 | $40.40M derived: sum of 2 quarters · filed 2017-10-31 | $56.10M 10-Q · filed 2017-10-31 | $69.80M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-06-30 | $17.20M 10-Q · filed 2017-08-02 | $32.90M 10-Q · filed 2017-08-02 | $46.60M derived: sum of 3 quarters · filed 2018-02-26 | $59.30M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2016-03-31 | $15.70M 10-Q · filed 2017-05-04 | $29.40M derived: sum of 2 quarters · filed 2018-02-26 | $42.10M derived: sum of 3 quarters · filed 2018-02-26 | $54.40M derived: sum of 4 quarters · filed 2018-02-26 | ||||
| 2015-12-31 | $13.70M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-26 | $26.40M derived: sum of 2 quarters · filed 2018-02-26 | $38.70M derived: sum of 3 quarters · filed 2018-02-26 | $50.10M 10-K · filed 2018-02-26 | ||||
| 2015-09-30 | $12.70M 10-Q · filed 2016-11-03 | $25.00M derived: sum of 2 quarters · filed 2016-11-03 | $36.40M 10-Q · filed 2016-11-03 | $49.50M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-06-30 | $12.30M 10-Q · filed 2016-08-08 | $23.70M 10-Q · filed 2016-08-08 | $36.80M derived: sum of 3 quarters · filed 2017-02-27 | $48.00M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2015-03-31 | $11.50M 10-Q · filed 2016-05-02 | $24.50M derived: sum of 2 quarters · filed 2017-02-27 | $35.70M derived: sum of 3 quarters · filed 2017-02-27 | $46.10M derived: sum of 4 quarters · filed 2017-02-27 | ||||
| 2014-12-31 | $13.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-27 | $24.20M derived: sum of 2 quarters · filed 2017-02-27 | $34.60M derived: sum of 3 quarters · filed 2017-02-27 | $44.30M 10-K · filed 2017-02-27 | ||||
| 2014-09-30 | $11.20M 10-Q · filed 2015-11-02 | $21.60M derived: sum of 2 quarters · filed 2015-11-02 | $31.30M 10-Q · filed 2015-11-02 | $40.40M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $10.40M 10-Q · filed 2015-08-05 | $20.00M 10-Q · filed 2015-08-05 | $29.20M derived: sum of 3 quarters · filed 2016-02-29 | $38.40M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | $9.60M 10-Q · filed 2015-05-05 | $18.80M derived: sum of 2 quarters · filed 2016-02-29 | $28.00M derived: sum of 3 quarters · filed 2016-02-29 | $37.40M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | $18.40M derived: sum of 2 quarters · filed 2016-02-29 | $27.80M derived: sum of 3 quarters · filed 2016-02-29 | $36.50M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $9.20M 10-Q · filed 2014-10-28 | $18.60M derived: sum of 2 quarters · filed 2014-10-28 | $27.30M 10-Q · filed 2014-10-28 | $36.50M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-06-30 | $9.40M 10-Q · filed 2014-07-31 | $18.10M 10-Q · filed 2014-07-31 | $27.30M derived: sum of 3 quarters · filed 2015-03-02 | $36.20M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2013-03-31 | $8.70M 10-Q · filed 2014-05-02 | $17.90M derived: sum of 2 quarters · filed 2015-03-02 | $26.80M derived: sum of 3 quarters · filed 2015-03-02 | $35.20M derived: sum of 4 quarters · filed 2015-03-02 | ||||
| 2012-12-31 | $9.20M derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-02 | $18.10M derived: sum of 2 quarters · filed 2015-03-02 | $26.50M derived: sum of 3 quarters · filed 2015-03-02 | $34.90M 10-K · filed 2015-03-02 | ||||
| 2012-09-30 | $8.90M 10-Q · filed 2013-10-28 | $17.30M derived: sum of 2 quarters · filed 2013-10-28 | $25.70M 10-Q · filed 2013-10-28 | $34.80M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-06-30 | $8.40M 10-Q · filed 2013-07-29 | $16.80M 10-Q · filed 2013-07-29 | $25.90M derived: sum of 3 quarters · filed 2014-02-26 | $34.00M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2012-03-31 | $8.40M 10-Q · filed 2013-04-29 | $17.50M derived: sum of 2 quarters · filed 2014-02-26 | $25.60M derived: sum of 3 quarters · filed 2014-02-26 | $33.00M derived: sum of 4 quarters · filed 2014-02-26 | ||||
| 2011-12-31 | $9.10M derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-26 | $17.20M derived: sum of 2 quarters · filed 2014-02-26 | $24.60M derived: sum of 3 quarters · filed 2014-02-26 | $31.90M 10-K · filed 2014-02-26 | ||||
| 2011-09-30 | $8.10M 10-Q · filed 2012-10-29 | $15.50M derived: sum of 2 quarters · filed 2012-10-29 | $22.80M 10-Q · filed 2012-10-29 | $29.80M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-06-30 | $7.40M 10-Q · filed 2012-08-02 | $14.70M 10-Q · filed 2012-08-02 | $21.70M derived: sum of 3 quarters · filed 2013-02-26 | $28.00M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2011-03-31 | $7.40M 10-Q · filed 2012-04-30 | $14.30M derived: sum of 2 quarters · filed 2013-02-26 | $20.60M derived: sum of 3 quarters · filed 2013-02-26 | $25.80M derived: sum of 4 quarters · filed 2013-02-26 | ||||
| 2010-12-31 | $6.90M derived: 10-K 12 month − 10-Q 9 month · filed 2013-02-26 | $13.20M derived: sum of 2 quarters · filed 2013-02-26 | $18.40M derived: sum of 3 quarters · filed 2013-02-26 | $23.30M 10-K · filed 2013-02-26 | ||||
| 2010-09-30 | $6.30M 10-Q · filed 2011-10-31 | $11.50M derived: sum of 2 quarters · filed 2011-10-31 | $16.40M 10-Q · filed 2011-10-31 | |||||
| 2010-06-30 | $5.20M 10-Q · filed 2011-08-01 | $10.10M 10-Q · filed 2011-08-01 | ||||||
| 2009-12-31 | $15.90M 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |